PEPTONIC medical AB (publ) issues its Annual Report 2018

PEPTONIC medical AB (publ)  –  today announces that its 2018 Annual Report is available on the Company’s website  and on the website of Spotlight

In the Auditor’s Report the following information is presented under the heading ‘Additional Information’ (in Swedish: ‘Övriga upplysningar’):

“We refer to the Annual Report that states that a need for additional financing may occur during the coming 12 months and that there is always the possibility to turn to the shareholders, however, there is no absolute guarantee that a rights issue will be successful.”

Johan Inborr, CEO
Mobile: + 46 708 853 893

pdf_symbol_35px  Download Annual report (In Swedish)

About VagiVital®

VagiVital®is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.

VagiVital®was launched in Sweden as a non-prescription self-care product in July 2018 (see 

About PEPTONIC medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital®is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (, ticker: PMED) in Stockholm, Sweden.